Finding blood and other clues for immune side effects
Part of Immune system & allergy clinical trials.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have any type of cancer
- You are currently being treated with immune checkpoint medicines (anti-PD-1 and/or anti-CTLA-4)
- You receive care at one of these hospitals: Amiens-Picardie University Hospital or Saint Quentin
- You have been fully told about the study and have signed the consent form
- Your treatment is not a “first-line” start of immune checkpoint medicine
- You are not taking MEK inhibitor medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
This study looks at blood vessel problems that may happen when people take immunotherapy (a type of cancer treatment that helps your immune system fight cancer). If you join, doctors will watch for these side effects and learn more about how to manage them.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks for markers in the blood that might predict side effects from immune checkpoint inhibitor therapy. By identifying these markers, doctors may better manage or prevent side effects for future patients.
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.